Dynavax Technologies (DVAX)
(Real Time Quote from BATS)
$11.16 USD
-0.03 (-0.27%)
Updated Aug 7, 2025 11:22 AM ET
4-Sell of 5 4
D Value D Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DVAX 11.16 -0.03(-0.27%)
Will DVAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DVAX
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates
Exelixis (EXEL) Beats Q2 Earnings Estimates
DVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dynavax Technologies (DVAX) Upgraded to Buy: Here's Why
Dynavax Technologies (DVAX) Reports Q1 Loss, Misses Revenue Estimates
TG Therapeutics (TGTX) Lags Q1 Earnings Estimates
Other News for DVAX
Here are the major earnings after the close Thursday
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Dynavax Technologies Corp (DVAX) Announces Q2 2025 Financial Results Release and Conference ...
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, ...
Wolverine Asset Management LLC Increases Stake in Future Vision II Acquisition Corp